Vaxart (VXRT) said late Monday it has completed enrollment of the 400 participants in the sentinel cohort for its phase 2b trial comparing its oral COVID-19 vaccine candidate with an approved mRNA vaccine.

The cohort includes 200 participants receiving Vaxart's vaccine and 200 receiving the mRNA comparator.

The primary endpoint of the study is the relative efficacy of Vaxart's vaccine candidate compared with the mRNA vaccine for the prevention of symptomatic disease, the company said.